What is MNMD's current stock price?

MNMD (Mind Medicine (MindMed) Inc.) is currently trading at $20.69 with a market cap of $1.56B.

What sector is Mind Medicine (MindMed) Inc. in?

Mind Medicine (MindMed) Inc. (MNMD) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is MNMD a good stock to buy?

Analysts have a Buy consensus on MNMD with a price target of $20.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

MNMD Mind Medicine (MindMed) Inc.

Healthcare

$20.69+0.44%ClosedMarket Cap: $1.56B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

8.78

P/S

0.00

EV/EBITDA

-10.62

DCF Value

$2.84

FCF Yield

-5.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-102.5%

ROA

-59.2%

ROIC

-60.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-77.1M	$—
Q4 null	$0.00	$-50.4M	$—
FY null	$0.00	$-183.8M	$—
Q3 null	$0.00	$-67.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$20.00

Target (Median)

$20.00

Target Range

$14.00 - $28.00

3 Strong Buy10 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Makes Brigiddirector

SellMon Jun 06

Makes Brigiddirector

SellMon Jun 06

Makes Brigiddirector

SellMon Jun 06

Greenway Schond L.officer: Chief Financial Officer

SellMon May 23

Greenway Schond L.officer: Chief Financial Officer

SellMon May 23

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.62

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Peers

KOD